Novartis AG Common Stock (NVS)

FairStock Score: 64/100 — STEADY

Key Financials

Strengths

• Generates $12.1 billion in annual free cash flow (4.3% yield on market cap)
• High return on equity of 30.8% demonstrating efficient capital deployment
• Attractive 3.2% dividend yield providing steady income returns
• FairStock composite score of 70/100 places it in the top tier across value, quality, and momentum factors
• Established organization with 75,267 employees providing operational scale

Concerns

• Trades significantly above Graham Number ($62) with negative 136% margin of safety—limited downside protection
• Anemic revenue growth of 2.2% for a company of this size limits long-term upside

AI Analysis

Novartis AG Common Stock is a mega-cap healthcare company valued at $284.0 billion. The business generates $56.7 billion in annual revenue with a 4.2% net margin and $12.1 billion in free cash flow. From a quality standpoint, Novartis shows Altman Z-Score of 2.9 in the grey zone and strong 31% ROE. On valuation, the stock is reasonably priced at 20.6x earnings, with trades far above its Graham Number ($62) with no margin of safety. Growth dynamics show revenue growing at 2.2% and profit growth of -14.5%. The 3.2% dividend yield adds an income component for patient holders. Our composite FairStock Score of 70/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Novartis's dominant market position and scale advantages create a durable moat that supports premium valuation over time. With $12.1 billion in annual free cash flow (4.3% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Sluggish 2% growth in a large-cap company leaves the stock vulnerable to de-rating if the market rotates toward higher-growth opportunities.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer